The global spread of Zika virus: is public and media concern justified in regions currently unaffected? by Narayan Gyawali et al.
OPINION Open Access
The global spread of Zika virus: is public
and media concern justified in regions
currently unaffected?
Narayan Gyawali, Richard S. Bradbury and Andrew W. Taylor-Robinson*
Abstract
Background: Zika virus, an Aedes mosquito-borne flavivirus, is fast becoming a worldwide public health concern
following its suspected association with over 4000 recent cases of microcephaly among newborn infants in Brazil.
Discussion: Prior to its emergence in Latin America in 2015–2016, Zika was known to exist at a relatively low prevalence
in parts of Africa, Asia and the Pacific islands. An extension of its apparent global dispersion may be enabled by climate
conditions suitable to support the population growth of A. aegypti and A. albopictus mosquitoes over an expanding
geographical range. In addition, increased globalisation continues to pose a risk for the spread of infection. Further,
suspicions of alternative modes of virus transmission (sexual and vertical), if proven, provide a platform for outbreaks in
mosquito non-endemic regions as well. Since a vaccine or anti-viral therapy is not yet available, current means of disease
prevention involve protection from mosquito bites, excluding pregnant females from travelling to Zika-endemic
territories, and practicing safe sex in those countries. Importantly, in countries where Zika is reported as endemic,
caution is advised in planning to conceive a baby until such time as the apparent association between infection
with the virus and microcephaly is either confirmed or refuted. The question arises as to what advice is appropriate to
give in more economically developed countries distant to the current epidemic and in which Zika has not yet been
reported.
Summary: Despite understandable concern among the general public that has been fuelled by the media, in regions
where Zika is not present, such as North America, Europe and Australia, at this time any outbreak (initiated by an infected
traveler returning from an endemic area) would very probably be contained locally. Since Aedes spp. has very limited
spatial dispersal, overlapping high population densities of mosquitoes and humans would be needed to sustain a focus
of infection. However, as A. aegypti is distinctly anthropophilic, future control strategies for Zika should be considered in
tandem with the continuing threat to human wellbeing that is presented by dengue, yellow fever and Japanese
encephalitis, all of which are transmitted by the same vector species.
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Background
The start of 2016 has been marked by global alarm over
the sudden and explosive emergence of a Zika virus
(ZIKV) outbreak in the majority of Latin American and
Caribbean countries, with estimated cases of 440 000–1
300 000 in Brazil alone [1, 2]. The virus has been linked
to more than 4 000 recent cases of microcephaly in
Brazil [3], a rare congenital disease that is associated
with incomplete brain development and which causes
babies to be born with unusually small heads and, in the
majority of cases, brain damage. It should be noted that
this association, whilst compelling still requires extensive
scientific study to be proven as attributable to congenital
ZIKV infection. Further research is already underway in* Correspondence: a.taylor-robinson@cqu.edu.auInfectious Diseases Research Group, School of Medical & Applied Sciences,
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Brazil, Colombia and El Salvador to understand the
effects of ZIKV in pregnant women [4].
Serological evidence has been shown recently to link
ZIKV infection with another neurological disorder,
Guillain-Barré syndrome (GBS), a neural demyelination
disorder often identified as being an autoimmune sequela
of infectious disease which causes acute or subacute flaccid
paralysis [5]. After a large cluster of microcephaly and GBS
was found to occur in areas newly infected with ZIKV, on
February 1st 2016 the International Health Regulations
Emergency Committee of the World Health Organization
declared ZIKV as “a public health emergency of inter-
national concern” and highlighted the importance of ag-
gressive measures to reduce infection, particularly among
pregnant women and women of childbearing age [6]. Sub-
sequently, the US Centers for Disease Control and Preven-
tion (CDC) have moved ZIKV to a level 1 activation [7],
the highest response level at the agency. This is significant
as within its three different operational areas of surveil-
lance, diagnostics and awareness, CDC collaborates with
international governments and their health agencies, in-
dustry partners at home and abroad, and with state and
local health departments to strengthen response efforts to
educate, alert and direct healthcare providers, media and
the public about the threat posed by Zika.
This article aims to provide a balanced perspective on
the possibility of a global spread of Zika, and the impact
this may have on those regions currently unaffected, in
light of growing public and media concern.
Causative agent of infection and clinical
manifestations of disease
Zika is a single-stranded, positive sense RNA virus [8], a
member of the Flaviviridae family that notably also
includes dengue, yellow fever and Japanese encephalitis
viruses, each of which is the cause of a significant re-
emerging infectious disease in humans. Zika was originally
isolated in 1947 from a Rhesus macaque that was captured
in the remote Zika forest of Uganda, East Africa, during
the course of mosquito and primate surveillance [9]. Sub-
sequently, the first human case was described in 1952 in
Nigeria [10].
Similarly to the globally established fellow flaviviruses
dengue and yellow fever, as well as the alphavirus chikun-
gunya, ZIKV is transmitted by species of Aedes mosqui-
toes, including the widespread A. aegypti and A. albopictus
[11]. Moreover, sexual contact has also been implicated as
a potential mode of transmission [12, 13]. This suspicion
has intensified further after the detection of ZIKV in a man
in the USA who had no travel history to any Zika-endemic
country but who did have a history of sexual contact with
a female from a Zika-endemic region [14].
Clinically, apart from the profound effects on the un-
born child apparently attributable to congenital infection,
Zika infection in humans is relatively benign. In adults it
is characterised as a mild, often unapparent, dengue-like
disease with fever, muscle pain, conjunctivitis, eye pain,
prostration and maculopapular rash [15]. In fact, around
four in five adults may be infected without showing any
clinical signs, in which instance they may act as asymp-
tomatic carriers of infection for a period of several days
after being bitten by an infectious mosquito [16].
Chronology of Zika outbreaks
Based on phylogenetic analysis, the earliest date of the
emergence of ZIKV is considered to be 1920 with a con-
fidence range of 1882–1947 [17]. The enzootic cycle of
ZIKV was maintained between wild primates and their
vectors, possibly Aedes mosquitoes and occasional hu-
man infection was considered as no more than inadvert-
ent spill over [18]. It is suspected that around 1945 the
virus transferred from Africa to South East Asia, where
it became geographically widespread by the 1960s [19].
In 2007, ZIKV emerged on the Micronesian island of
Yap, the detection of which was suspected as an Asian
lineage virus [20]. A subsequent outbreak occurred in
2013 and 2014 in French Polynesia, which was associ-
ated with 42 cases of GBS [21]. A serological finding of
0.8 % antibody positivity to ZIKV in that region suggests
that the virus was not introduced prior to the outbreak
[22]. A phylogenetic assessment found the Polynesian
ZIKV to be very closely related to South East Asian
strain. In the last year, further spread has occurred in
several countries of Oceania, including New Caledonia,
the Cook Islands and Easter Island [23].
From the start of 2015, patients with Zika symptoms
began to be reported in the north-east of Brazil [24].
The presence of Aedes mosquitoes across Latin America
coupled with a suitable climate for their population
growth, combined with an ever increasing movement of
people globally, appears to have triggered the current
remarkable rise in Zika cases. Moreover, as the region is
presumed to be a novel location for Zika, the inhabitants
will likely not have any prior exposure to ZIKV and thus
will not have ever produced specific antibodies, which
act as natural vaccine against the virus. In circumstances
that are distinct from the sporadic infections which have
arisen within populations in Africa and Asia for several
decades, in the present Zika epidemic a substantial num-
ber of people must have been affected over a short period
of time in order for the outbreak to expand rapidly from
its initial localized focus of infection.
By the end of 2015, ZIKV had spread to at least 18 states
of Brazil. The strain of ZIKV in Latin America is thought
to have originated from the Pacific islands, quite possibly
brought into Brazil by one or more infected persons asso-
ciated with a mass gathering such as a carnival or sporting
event [1]. As an example, the international canoe race,
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which was held in Rio de Janeiro, Brazil, in August 2014
involved the participation of athletes from four Pacific
Ocean territories (French Polynesia, New Caledonia, Cook
Islands and Easter Island). Introduction by Brazilian
travellers returning from the Pacific islands also cannot
be excluded. By the start of March 2016, ongoing trans-
mission of ZIKV has now been reported in 34 South
and Central American countries and territories (Fig. 1).
Hitherto considered for many years to be of little
clinical or epidemiological importance, why this Zika
epidemic has occurred now in such an explosive fash-
ion throughout the Americas is not entirely clear,
although inadequate mosquito control might be impli-
cated as one contributing factor. In many ways, Zika is a
prime example of a re-emerging infectious disease; an old
disease presenting in large numbers and in a new context.
Global spread and risk to mosquito non-endemic
regions
The risk of local transmission of ZIKV and the threat of
outbreaks is equal for all the countries where mosqui-
toes susceptible to or competent for ZIKV are found.
Such species include Aedes aegypti, A. albopictus, A.
luteocephalus, A. unilineatus and A. vittatus [25]. The
potential for A. aegypti and A. albopictus - well known
vectors for dengue, yellow fever and chikungunya – to
transmit ZIKV is acknowledged. However, some strains
within the same species may not be able to transfer
ZIKV [26, 27]. Nonetheless, nations that are endemic for
dengue, yellow fever and chikungunya are potentially at
risk for Zika. It may be that a similar pattern of global
spread could be observed when Zika, dengue and chi-
kungunya are compared. Chikungunya was first identi-
fied in Africa before reaching South Asia, South East
Asia, Pacific islands and the Americas [28]. However,
no sufficiently well-defined and robust mathematical
model of epidemiology applies to any communicable
infectious disease [29].
Increased globalisation continues to pose a risk for
disease spread. The breakdown of the destination of
international travellers (9.9 million in 2015) flying from
Brazilian airports (ZIKV-affected area) to North America,
Europe, Asia and Africa are 65, 27, 5 and 3 %, respectively
[30]. Taken together, the earlier experiences of the route
of spread of dengue and chikungunya and the current data
on people travelling from Brazil to overseas, point to the
threat of ZIKV potentially spreading across Latin America,
the Caribbean and into southern parts of the USA. By
early March 2016, 153 travel-associated and 107 locally
acquired Zika cases had been reported in the USA and in
its territories [31]. In Asia, although there are no reports
of severe outbreaks yet, sporadic cases have being de-
scribed from different parts of that region [32–35]. The
isolation of ZIKV from a mosquito in Malaysia in the
1960s [19] suggests that the virus has existed there for a
long time and so may have caused morbidity for many
years, probably being underreported due to confusion
of diagnosis with dengue fever, pyrexia of unknown ori-
gin or other unknown diseases. Serological or phylo-
genetic studies are required in order to determine the
extent of the spread of ZIKV in regions of South Asia,
where dengue already has a strong presence. It may be
possible that people in such areas could have developed
antibodies through infection with ZIKV over an extended
period, which could provide a naturally acquired form of
prophylaxis. This possibility lowers the assumed risk of
the immediate spread and outbreaks of Zika in tropical
parts of Asia.
In addition to the spread of Zika via mosquito bite,
the current news media is awash with stories regarding
the possibilities of sexual, blood-borne and vertical
transmission of ZIKV. In a scenario in which one or
more of these routes proves to be a potential mode of
transmission, paradoxically the effect may be to facili-
tate any outbreak of Zika in those areas regardless of
Aedes mosquito availability. This would pose a serious
Fig. 1 Current regions of known Zika virus endemicity [3]
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threat for the global spread of ZIKV and thus consti-
tutes a major public health problem.
Limited risk of local transmission in currently
unaffected regions
While it is possible that the distribution of Zika in the
Asia Pacific region could eventually reach as far as
Australia, it should be containable in this and other
developed countries where Aedes spp. mosquitoes are
found through adherence to current measures of mos-
quito control. Such vector control programs are in place
to combat dengue, yellow fever and Japanese encephal-
itis. It is highly likely that any outbreak initiated by an
infected index case returning from overseas would be
locally restricted, just like current dengue outbreaks that
occur sporadically in northern Queensland [36]. As A.
aegypti has a very limited flight range [37], to sustain a
significant outbreak requires a high population density of
both mosquitoes and humans. In this context, it should be
noted that this is a mosquito species that thrives in urban
environments which is a consideration for future control
programs, both for Zika itself but also in unison with the
ongoing public health threat posed by dengue and other
medically important arboviruses.
Strategies to combat ZIKV
There is no vaccine available to immunize people against
Zika. Since ZIKV is a relative of yellow fever and Japanese
encephalitis viruses, for which efficacious vaccines are
available [38], there is hope that a similar preparation can
be developed against Zika but this may take several years
to design, trial and gain regulatory approval for public
administration [39]. With anti-viral therapy also not avail-
able, at present alternative interventions are being used to
combat Zika. These include low technology measures that
focus on vector control such as insecticide spraying, limit
mosquito breeding and providing protection from mos-
quito bites [40]. Aedes mosquitoes are active and bite
during the day [41], so use of an effective repellent is
highly recommended. The fitting of house door and win-
dow screens, use of air-conditioning, removal of yard and
household debris and containers (e.g. disposed tyres,
broken bowls and cups, flower vases) that provide breed-
ing sites for mosquitoes, are all measures that contribute
to control of the vector within a local community [40].
Integrated vector management (IVM), advocated by the
World Health Organization as a method of combating
Aedes transmission of dengue [42], would also be an ap-
propriate strategy for ZIKV. IVM is defined as “a rational
decision-making process for the optimal use of resources
for vector control”, where an integrated collaborative sec-
tor implements evidence-based selection and delivery of
different interventions (or combinations of interventions)
that are informed by, and thereby tailored to, local settings
[42]. Until such time as the apparent association between
ZIKV infection and microcephaly is either established or
disproved, women should be cautious in planning to con-
ceive a baby or to travel to a Zika-endemic country if
already pregnant. An effective approach to surveillance of
infection among pregnant women, at least in current en-
demic regions, should be initiated [43]. While the mooted
possibility of sexual and vertical transmission of ZIKV re-
mains to be substantiated [13], practicing safe sex in Zika
‘hot spots’ would beneficially reinforce existing protection
programs against sexually transmitted diseases including
HIV/AIDS. The real possibility of ZIKV transmission
through blood transfusion should not be ignored [44].
Thus, if not already in place, a stringent safety policy for
managing blood and blood products should be established
and practiced.
Research priorities to prevent a ZIKV pandemic
Given the magnitude of the current explosive spread of
Zika [1, 2], public and private key stakeholders, funding
agencies and public health experts worldwide should
consider what issues need to be prioritised for research
in order to produce effective approaches to combat
ZIKV. Very little is known about this virus [45]; the
shortfall in research includes epidemiological character-
istics, surveillance and diagnostics, virus reservoirs/vec-
tors/transmission, disease manifestations and sequelae,
clinical management and public health interventions.
The drivers responsible for Zika emergence and out-
break are evidently complex and multifactorial [45].
This collective knowledge gap demands urgent action
to characterise better both the virus and the pathologies it
causes, especially those related to infection during preg-
nancy, which represents a serious public health challenge.
Beyond short term emergency management of the Latin
American epidemic [6, 7], a major consideration is to re-
search strategies for prevention of a global pandemic, in-
cluding effective vaccine development and implementation
of vector control programs.
Conclusions
The recent striking emergence of cases of Zika in Latin
America poses a threat for a worldwide outbreak of this
mosquito-borne viral infection. The globalisation of the
human population promotes the movement of asymp-
tomatic carriers between countries in the same or dif-
ferent continents. Pregnant women are considered a
high-risk group for Zika, as infection is strongly associ-
ated with, if as yet unproven as a cause of, microceph-
aly in the developing foetus. Furthermore, increasing
suspicion of diverse modes of virus transmission, sexual
and vertical, if confirmed, makes the life cycle of the
virus extremely complex and limits the scope of pre-
dictive models, which in turn may impede control
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efforts. No vaccine has been developed yet and even
though this has been prioritised by multiple funding
agencies, it may take several years to become commer-
cially available. In this context, performing clinical trials
on pregnant women would present difficult practical
and ethical hurdles to overcome.
Overall, the public health challenges presented by
ZIKV raise a significant threat for a global outbreak un-
less and until the current deficit of knowledge relating
to the epidemiology of this virus is rectified. In more
economically developed countries, however, Zika may
not have the same impact as it is making in regions in
which there is insufficient funding or infrastructure to
support effective implementation of mosquito control
programs. In this regard, it would be appropriate to
consider Zika as an infectious disease of poverty. ZIKV
may spread to countries adjoining those now heavily af-
fected and small scale, easily controlled, outbreaks may
occur through travel in industrialised nations. However,
given the significant capacity for mosquito control in
developed countries, we consider that the widespread
public and media concern regarding the spread of Zika
to, and potential to reach epidemic proportions in, cur-
rently unaffected industrialised nations as difficult to
justify.
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